Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125287872 | 12528787 | 2 | F | 201604 | 20160916 | 20160705 | 20160923 | EXP | FR-PFIZER INC-2016317094 | PFIZER | 81.00 | YR | M | Y | 0.00000 | 20160923 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125287872 | 12528787 | 1 | PS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Oral | 1 DOSAGE FORM (4 MG), 1X/DAY | Y | 22030 | 4 | MG | PROLONGED-RELEASE TABLET | QD | |||||
| 125287872 | 12528787 | 2 | SS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Y | 22030 | PROLONGED-RELEASE TABLET | ||||||||||
| 125287872 | 12528787 | 3 | SS | TOVIAZ | FESOTERODINE FUMARATE | 1 | Y | 22030 | PROLONGED-RELEASE TABLET | ||||||||||
| 125287872 | 12528787 | 4 | SS | PRAVASTATIN SODIUM. | PRAVASTATIN SODIUM | 1 | Oral | 40 MG, 1X/DAY | Y | 0 | 40 | MG | TABLET | QD | |||||
| 125287872 | 12528787 | 5 | SS | GUTRON | MIDODRINE | 1 | Oral | 2.5 MG, UNK | Y | 0 | 2.5 | MG | TABLET | ||||||
| 125287872 | 12528787 | 6 | SS | XELEVIA | SITAGLIPTIN PHOSPHATE | 1 | 1 DF (100 MG) ONCE DAILY | Y | 0 | 100 | MG | FILM-COATED TABLET | QD | ||||||
| 125287872 | 12528787 | 7 | C | AMIODARONE HYDROCHLORIDE. | AMIODARONE HYDROCHLORIDE | 1 | Oral | 0 | |||||||||||
| 125287872 | 12528787 | 8 | C | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | 75 MG, UNK | 0 | 75 | MG | POWDER FOR ORAL SOLUTION | |||||||
| 125287872 | 12528787 | 9 | C | SYMBICORT | BUDESONIDEFORMOTEROL FUMARATE DIHYDRATE | 1 | Respiratory (inhalation) | 0 | |||||||||||
| 125287872 | 12528787 | 10 | C | INSULIN | INSULIN NOS | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125287872 | 12528787 | 1 | Pollakiuria |
| 125287872 | 12528787 | 2 | Urinary incontinence |
| 125287872 | 12528787 | 3 | Urge incontinence |
| 125287872 | 12528787 | 4 | Cardiovascular disorder |
| 125287872 | 12528787 | 5 | Orthostatic hypotension |
| 125287872 | 12528787 | 6 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125287872 | 12528787 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125287872 | 12528787 | Condition aggravated | |
| 125287872 | 12528787 | Fall | |
| 125287872 | 12528787 | Orthostatic hypotension |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125287872 | 12528787 | 1 | 20160514 | 20160525 | 0 | |
| 125287872 | 12528787 | 4 | 20160525 | 0 | ||
| 125287872 | 12528787 | 5 | 20160530 | 0 | ||
| 125287872 | 12528787 | 6 | 20160525 | 0 |